Ginseng, a traditional medicinal herb with a favorable safety profile, has long been used to promote systemic health. Recent studies reveal that many of its beneficial effects are mediated through interactions with the gut microbiota. Microbial enzymes convert parent ginsenosides into more absorbable and bioactive metabolites such as compound K, while ginseng reciprocally remodels the microbial community and metabolite composition by promoting the growth of beneficial taxa including Akkermansia , Bifidobacterium , and Lactobacillus . These bidirectional interactions modulate host metabolic, immune, and intestinal barrier functions. The ginseng–microbiome interplay regulates microbial and host-derived metabolites such as short-chain fatty acids, bile acids, and indole derivatives, which in turn activate key signaling pathways including FXR/TGR5, FFAR, AMPK, and Nrf2. Through these mechanisms, ginseng improves lipid metabolism, enhances insulin sensitivity, alleviates low-grade inflammation, and ameliorates metabolic abnormalities such as obesity, insulin resistance, and nonalcoholic fatty liver disease (NAFLD). This review provides a comprehensive synthesis of the ginseng–microbiota metabolic axis, focusing on its mechanistic basis in metabolic regulation and related disorders. We also highlight the therapeutic convergence between ginseng and probiotics possessing ginsenoside-hydrolyzing enzymes, discuss strategies for strain selection and co-administration, and outline future directions in precision, microbiome-informed formulations and clinical trial design. Collectively, current evidence supports the ginseng–microbiota interactions as a promising therapeutic platform for restoring metabolic homeostasis and managing metabolic diseases.
Kang et al. (Sun,) studied this question.